Mid-cap information technology solutions player, Mastek, posted a net profit of Rs 7.6 crore for the quarter ended December, against a net loss of Rs 1.52 crore in the corresponding quarter last year. Revenue grew 31% at Rs 230 crore from Rs 176 crore reported in the same quarter last year. Mastek added three new clients during the quarter under review. “What gives me pleasure is the strong order backlog of R538 crore, which is a historical high,” said Sudhakar Ram, chairman and group CEO, Mastek.
Alembic Pharma Q3 net up 9.13% at R48.27 crore
Alembic Pharmaceuticals on Monday said its net profit rose by 9.13% to R48.27 crore for the third quarter ended December. The company had posted net profit of R44.23 crore in the same period of previous fiscal, Alembic said in a filing to the BSE. Net sales of the company declined, however, to R372 crore during the quarter, from R383 crore during the same period of the 2011-12 fiscal. Alembic said its domestic formulation sales rose to R228 crore during the third quarter ended December, from R199 crore during the same period of the previous fiscal.
Tata Capital to fund Nissan arm customers, fleet owners
Nissan’s national sales company in India – Hover Automotive India - has announced a new preferential financier agreement with Tata Capital Financial Services, making Nissan’s growing model range even more accessible to potential customers. Hover Automotive India (HAI) is Nissan’s sole and exclusive Indian distributor. The tie-up with Tata Capital — one of India’s leading financial solutions providers — will prove attractive to both private and fleet customers and dealers, nationwide. Under the terms of the agreement, Tata Capital will offer attractive 100% ex-showroom funding on the purchase of Nissan models and salaried customers can avail loans without any proof of income.
Trivitron, BioSystems set up JV for IVD reagents
Trivitron, one of the leading medical equipment manufacturer in India, has joined hands with BioSystems of Spain to set up a joint venture facility called Biosystems Diagnostics (BDPL) to manufacture In Vitro Diagnostics reagent in India for emerging markets. Indigenous manufacturing of high quality IVD reagents at the Trivitron Medical Technology Park will enhance access to cost effective diagnosis, said GSK Velu, founder and managing director, Trivitron Healthcare. Trivitron Medical Technology Park is South Asia’s first of its kind manufacturing facility situated at Irungattukottai near Chennai.
Helios & Matheson bags contract from US auto co
IT company Helios and Matheson Information, through its subsidiary Matheson Information Technology, has bagged a three-year contract for providing managed services to a Fortune 500 major US automotive giant. Declining to divulge the identity of the company and size of the deal, Helios and Matheson CEO and MD GK Muralikrishna said, “It is a multi-million contract and and will be adding to our revenues substantially.” He said that though the client has been associated with the company for over 13 years, the order is new.
Lamborghini global sales jump 30% in 2012
Italian luxury car-maker Lamborghini on Monday said its global sales increased by over 30% to 2,083 units in 2012 driven by robust performance in many markets, including India. “Automobili Lamborghini SpA increased worldwide deliveries to customers in 2012 from 1,602 to 2,083 units... strong demand continues for award-winning Aventador,” the company said in a statement. During the year, the Asia Pacific region contributed 35% of the global total sales. “India achieved sales growth of 21%,” Automobili Lamborghini said without sharing details.
Audi launches new version of R8 sportscar
German luxury carmaker, Audi, has launched the new version of its two-seater R8 sportscar in India priced at R1.34 crore for the V8 version and R1.57 crore for the V10 model. A V10 convertible variant is also available at R1.73 crore. The segment leader, R8 sees new headlights and improved acceleration on all models. The R8 V8 puts out 430 HP, while the V10 variant puts out 525 hp of power, propelling the car from 0 to 100 kmph in 3.6 seconds up to a top speed of 314 kmph.
Aurobindo gets FDA nod for anti-bacterial injections
Aurobindo Pharma on Monday said it has received final approvals from the US health regulator to manufacture and market Oxacillin for Injection used for treating bacterial infections in the American market. The company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Oxacillin for Injection USP, packaged in 1g and 2g vials and Oxacillin for Injection USP 10g/vial pharmacy bulk package, Aurobindo Pharma said in a statement.
Be the first to comment.